CAN FITE BIOPHARMA LTD-ADR (CANF)
US13471N3008 - ADR
CAN FITE BIOPHARMA LTD-ADR
NYSEARCA:CANF (1/8/2025, 8:04:01 PM)
After market: 1.57 0 (0%)1.57
-0.09 (-5.42%)
Company Profile
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Company Info
CAN FITE BIOPHARMA LTD-ADR
26 Ben Gurion Street
Ramat Gan 4951778
P: 97239241114
CEO: Pnina Fishman
Employees: 5
Website: https://www.canfite.com/
CANF News
10 days ago - Can-Fite BioPharma Ltd.Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug NamodenosonCan-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver...
a month ago - Can-Fite BioPharma Ltd.8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson DrugRAMAT GAN, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a...
2 months ago - ACCESSWIRE60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV2 months ago - Can-Fite BioPharma Ltd.Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialOrphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American:...
2 months ago - Can-Fite BioPharma Ltd.Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in AustraliaNamodenoson is an oral drug with a proven favorable safety profile RAMAT GAN, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd....
3 months ago - Can-Fite BioPharma Ltd.Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with PiclidenosonData Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan,...
CANF Twits
Here you can normally see the latest stock twits on CANF, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
